Phathom Pharmaceuticals Stock Beta
| PHAT Stock | USD 6.79 0.17 2.44% |
Phathom Pharmaceuticals fundamentals help investors to digest information that contributes to Phathom Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Phathom Stock. The fundamental analysis module provides a way to measure Phathom Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Phathom Pharmaceuticals stock.
Phathom | Beta |
Phathom Pharmaceuticals Company Beta Analysis
Phathom Pharmaceuticals' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Phathom Pharmaceuticals Beta | 0.72 |
Most of Phathom Pharmaceuticals' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Phathom Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Phathom Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Phathom Pharmaceuticals is extremely important. It helps to project a fair market value of Phathom Stock properly, considering its historical fundamentals such as Beta. Since Phathom Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Phathom Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Phathom Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Phathom Pharmaceuticals has a Beta of 0.718. This is 16.51% lower than that of the Pharmaceuticals sector and 48.35% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Phathom Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Phathom Pharmaceuticals' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Phathom Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Phathom Pharmaceuticals by comparing valuation metrics of similar companies.Phathom Pharmaceuticals is currently under evaluation in beta category among its peers.
Phathom Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Phathom Pharmaceuticals from analyzing Phathom Pharmaceuticals' financial statements. These drivers represent accounts that assess Phathom Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Phathom Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 1.1B | 727.8M | 438.9M | 468.3M | 538.5M | 682.0M | |
| Enterprise Value | 865.4M | 635.9M | 380.6M | 225.9M | 259.8M | 246.8M |
Phathom Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Phathom Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Phathom Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Phathom Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Phathom Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Phathom Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Phathom Pharmaceuticals' value.| Shares | Gilder Gagnon Howe & Co Llc | 2024-09-30 | 1.6 M | Checkpoint Capital Lp | 2024-09-30 | 1.5 M | Orbimed Advisors, Llc | 2024-09-30 | 1.4 M | Federated Hermes Inc | 2024-09-30 | 1.4 M | Fmr Inc | 2024-09-30 | 1.3 M | Decheng Capital Llc | 2024-09-30 | 1.2 M | Gw&k Investment Management, Llc | 2024-09-30 | 1.1 M | Catalys Pacific Llc | 2024-09-30 | 1.1 M | 683 Capital Management Llc | 2024-09-30 | 1 M | Medicxi Ventures Management (jersey) Ltd | 2024-09-30 | 7.5 M | Jennison Associates Llc | 2024-09-30 | 5.9 M |
As returns on the market increase, Phathom Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Phathom Pharmaceuticals is expected to be smaller as well.
Phathom Fundamentals
| Return On Equity | -34.89 | ||||
| Return On Asset | -0.58 | ||||
| Operating Margin | (4.33) % | ||||
| Current Valuation | 317.64 M | ||||
| Shares Outstanding | 68.38 M | ||||
| Shares Owned By Insiders | 7.72 % | ||||
| Shares Owned By Institutions | 92.28 % | ||||
| Number Of Shares Shorted | 14.95 M | ||||
| Price To Book | 25.37 X | ||||
| Price To Sales | 18.12 X | ||||
| Revenue | 682 K | ||||
| Gross Profit | 21.95 M | ||||
| EBITDA | (159.05 M) | ||||
| Net Income | (201.59 M) | ||||
| Cash And Equivalents | 207.39 M | ||||
| Cash Per Share | 5.39 X | ||||
| Total Debt | 139.03 M | ||||
| Debt To Equity | 2.43 % | ||||
| Current Ratio | 9.93 X | ||||
| Book Value Per Share | (2.74) X | ||||
| Cash Flow From Operations | (137.58 M) | ||||
| Short Ratio | 14.87 X | ||||
| Earnings Per Share | (5.74) X | ||||
| Target Price | 24.86 | ||||
| Number Of Employees | 452 | ||||
| Beta | 0.72 | ||||
| Market Capitalization | 475.91 M | ||||
| Total Asset | 413.84 M | ||||
| Retained Earnings | (928.68 M) | ||||
| Working Capital | 358.65 M | ||||
| Net Asset | 413.84 M |
About Phathom Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Phathom Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Phathom Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Phathom Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.